|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for MSLN(NM_013404.3) Search again
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
Summary
An antibody that reacts with ovarian cancers and mesotheliomas was used to isolate a cell surface antigen named mesothelin. Although the function of mesothelin is unknown, it may play a role in cellular adhesion and is present on mesothelium, mesotheliomas, and ovarian cancers. This gene encodes a preproprotein that is cleaved into two products, megakaryocyte potentiating factor and mesothelin. Alternative splicing results in multiple transcript variants. [provided by RefSeq].
Gene References into function
- binding of membrane-bound mesothelin to ovarian cancer antigen CA125 mediates heterotypic cell adhesion
- mesothelin is highly expressed in several human cancers [review]
- Elevated serum mesothelin is associated with mesothelioma and ovarian cancer
- The mesothelin expression is associated with prolonged survival in patients with high-grade ovarian serous carcinoma.
- MSLN, a tumor marker, is also used as a target for immunotherapy.
- MPF is secreted by several mesothelioma cell lines and is frequently elevated in the blood of patients with mesothelioma
- Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
- Mesothelin was expressed in 5 (50%) of 10 adenocarcinomas, 1 (17%) of 6 high-grade dysphasia/adenocarcinoma in situ cases, and 0 low-grade dysplasia.
- We present evidence that during cell division the decreasing activity of MPF acts as a master signal, which utilizes different thresholds to control initiation of different mitotic events. The key temporal control here is the degradation of cyclin B1.
- Primary acute myeloid leukemia cells express mesothelin
- an immunohistochemical panel including CK7,CD10 and mesothelin is optimal for distinguishing between ovarian and renal clear cell carcinoma.
- Mesothelin is not useful in the differential diagnosis of lung adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma.
- data support soluble mesothelin-related peptide as a promising marker for malignant pleural mesothelioma in both serum and pleural effusion fluid in asbestos-exposed cohorts
- mesothelin expression,production in supernatants from epithelioid MPM cell lines
- Overexpression of MSLN resulted in sustained activation of extracellular signal-regulated kinase 1/2 and suppression of Bim.
- expression in <50% of tumor cells is a negative prognostic marker in malignant mesothelioma
- Novel functions of mesothelin and a new therapeutic vaccine strategy whereby mesothelin is targeted to control pancreatic cancer progression.
- Extremely high mesothelin levels were associated with mesothelioma
- These findings suggest that mesothelin is expressed in at least some arachnoid and meningioma cells.
- diagnostic value of Megakaryocyte potentiating factor for malignant pleural mesothelioma was better than that of mesothelin although both markers showed almost equal specificity for MPM
- Assays measuring SMRP in serum and other bodily fluids are likely to be clinically useful for patients with ovarian cancer.
- Elevated megakaryocyte potentiating factor serum levels are associated with malignant mesothelioma.
- Significantly higher soluble mesothelin-related protein is associated with malignant pleural mesothelioma.
- data indicate overexpression of MSLN in pancreatic cancer cells leads to constitutive activation of Stat3, resulting in enhanced expression of cyclin E & cyclin E/cyclin-dependent kinase 2 complex formation & increased G(1)-S transition
- analysis of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma
